Transmission roles of symptomatic and asymptomatic COVID-19 cases: a modeling study

Authors:

Jianbin Tan[1]†, Yang Ge[2]†, Leonardo Martinez[3], Zhiping Chen[4], Changwei Li[5], Adrianna Westbrook[2], Enfu Chen[4], Jinren Pan[4], Yang Li[6], Feng Ling[4], Jimin Sun[4]‡, Hui Huang[1]‡, Ye Shen[2]‡.

Author affiliations:

[1]Sun Yat-Sen University, School of Mathematics, Guangzhou, China;
[2]University of Georgia, College of Public Health, Department of Epidemiology and Biostatistics, Athens, Georgia, United States;
[3]Stanford University, School of Medicine, Division of Infectious Diseases and Geographic Medicine, Stanford, California, United States;
[4]Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China;
[5]Tulane University School of Public Health and Tropical Medicine, Department of Epidemiology, New Orleans, Louisiana, United States;
[6]Renmin University of China, School of Statistics, Beijing, China.

† Joint first authors; ‡ Joint senior authors.

Corresponding Author:

Dr. Ye Shen, University of Georgia, College of Public Health, Department of Epidemiology and Biostatistics, Athens, Georgia, United States

Word count: 3485.

Key words: COVID-19, SARS-CoV-2, age-dependent contact, asymptomatic case, transmission

Conflict of interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Abstract

Objective

Age-dependent asymptomatic and symptomatic transmission dynamics of COVID-19 have not been well quantified due to limited data.

Methods

Through a population-based surveillance network, we collected data on 1342 confirmed cases with a 90-days follow-up for all asymptomatic cases.

Results

The difference in transmissibility of a symptomatic and asymptomatic case depended on age and was most distinct for the middle-age groups. The asymptomatic cases had a 66.72% lower transmissibility rate than symptomatic cases, and 74.10% (95%CI: 65.85% - 80.72%) of all asymptomatic cases were missed in detection. The average proportion of asymptomatic cases was 28.22% (95%CI: 22.97% - 34.56%). Simulation showed that the burden of asymptomatic transmission increased as the epidemic continued and could potentially dominate the spreading.

Conclusion

Asymptomatic COVID-19 cases play a significant role in transmission. Vaccine Strategies prioritizing the population between 30-60 years old are likely to have the most population-level benefits.

Background

COVID-19, caused by the novel coronavirus (SARS-CoV-2),[1] is a great threat to human health.[2] Nonpharmaceutical interventions such as social distancing, case isolation and contact quarantines are the most common tools for suppressing the pandemic in many countries where vaccine supplements are limited.[3–5] However, these interventions are less effective in asymptomatic transmission prevention and control.[6]

COVID-19 patients may present and remain pre-symptomatic, asymptomatic, or symptomatic and transmission may occur at each of these disease states.[7–9] Unlike the transmission caused by symptomatic cases, pre-symptomatic and asymptomatic transmission are hard to detect and difficult to measure as many surveillance systems rely on symptom-based population screening.[7,10–12] Previous case studies suggested that asymptomatic COVID-19 individuals are less infectious than symptomatic cases.[13,14] However, asymptomatic cases may spread for a longer period due to reduced efficiency in case detection.[15] Several studies investigated the silent transmission of SARS-CoV-2, but presented contradictory conclusions with estimated burden ranged from 3% to 79%.[15–17]

Without sufficient follow-up time, asymptomatic and pre-symptomatic cases are often indistinguishable. Consequently, studies using population-level data to estimate of age-specific transmission and susceptibility parameters commonly falls short of accuracy which potentially explains for the heterogeneous findings from different studies.[18–20]

42 Common issues were modeling without data on observed asymptomatic infection[15–17,21]
43 and inclusion of pre-symptomatic cases as part of an asymptomatic classification,[18–20].
44 Meanwhile, few studies assessing asymptomatic infectiousness and viral load with
45 limited sample sizes fail to capture the transmission dynamics.[13,14,22–29] No studies to
46 date have attempted to combine reliable case symptom classification with
47 age-dependent transmissibility, social contact measures, and susceptibility parameters
48 at the population level to learn the transmission dynamics. However, a comprehensive
49 understanding of the age-specific symptomatic and asymptomatic transmission
50 dynamics at the population level is essential to the evaluation of an epidemic and the
51 creation of responding health policies.
52
53 In this study, we report on a longitudinal cohort of all diagnosed COVID-19
54 infections, between January 7th and February 22nd, 2020, from Zhejiang province, China.
55 All patients without initial symptoms were followed by at least 90 days to distinguish
56 between asymptomatic and pre-symptomatic cases, an essential procedure rarely
57 implemented by previous studies to ensure reliable classification of case symptoms. We
58 then built age-stratified compartmental models to study the age-dependent
59 population-level transmission roles of symptomatic and asymptomatic COVID-19 cases.

Methods

Data sources

Zhejiang province is an eastern coastal province adjacent to Shanghai city with a population of approximately 54 million individuals.[30] The first and only major wave of the COVID-19 epidemic in Zhejiang began on January 7th, 2020 and continued until February 22nd, 2020 after which only sporadic single-case events were observed. We included information from all confirmed cases in this major wave (a total of 1342 cases), as well as a follow-up investigation related to all detected asymptomatic infections to distinguish between asymptomatic and pre-symptomatic cases. Individual-level data related to the symptom onset of symptomatic infections, as well as COVID-19 confirmation dates and ages of both symptomatic and asymptomatic cases were collected. For the contact data, we obtained contact matrices between age groups from surveys conducted in Shanghai.[31,32] Other primary sources of data used in our analyses include the population census data of Zhejiang province[30] and the estimated age-dependent susceptibility of COVID-19 from a previous study.[21]

On January 23rd ,2020, the provincial government changed its infectious disease alert category to the highest level and, on February 1st, began a comprehensive set of interventions.[33] As of April 10th, 2020, the date in which we restricted our data for this analysis, no additional outbreak had been observed. Trained health professionals investigated each confirmed case with a predefined questionnaire by which basic health and demographic information were collected.

82

83 Definition of symptomatic and asymptomatic cases

84 All confirmed cases and their close contacts were isolated or quarantined after
85 being identified through contact tracing. During the isolation/quarantine period, cases
86 and their contacts received regular testing and daily symptom screening for fever,
87 cough, and shortness of breath. Tests for case confirmation were conducted using
88 reverse transcription polymerase chain reaction (RT-PCR) or viral genome sequencing on
89 samples from throat swabs (oropharynx and nasopharynx). If a case or contact had a
90 positive test result but without any symptoms, they would be temporarily classified as
91 an asymptomatic/pre-symptomatic case at the time. All cases were followed for at least
92 90 days after their initial positive test to distinguish between asymptomatic and
93 pre-symptomatic cases. Among these subjects, those who developed symptoms later
94 would receive a final classification as a symptomatic case. Others who had never
95 developed any symptoms between their initial positive test and first subsequent
96 negative PCR test would be classified as asymptomatic cases.

97

98 Model structure

99 We divided the total population of Zhejiang province into seven age groups:
100 0-10, 10-20, 20-30, 30-40, 40-50, 50-60, 60+. To consider transmission related to
101 symptomatic and asymptomatic infections among different age groups, our model
102 contained 8 compartments for the ith age group: susceptible population (S^i), exposed
103 contacts (E^i), pre-symptomatic cases (I_{ps}^i, infected but have not yet developed

symptoms), symptomatic cases (I_s^i), asymptomatic cases (I_a^i, infected but asymptomatic till confirmed/recovery), and removed/recovery groups (R_{cs}^i, R_{ca}^i, R_h^i). We assumed new infections were driven by transmission from compartments of I_{ps}^i, I_s^i and I_a^i in all age groups. Asymptomatic cases (I_a^i) were infections without typical symptoms. These infections were difficult to identify through symptom-based screening; therefore, underreporting in this category of infections was notable. While some asymptomatic cases may have been quarantined through contact tracing, others may have remained unnoticed throughout the entirety of their transmissibility. As such, it is essential to consider unconfirmed asymptomatic cases, also referred as the self-recovered asymptomatic cases (R_h^i in Figure 1) in modeling. For all age groups, the details of the compartments are given in Table 1, and the state transitions in the compartmental model are given in Figure 1.

<u>Social contacts</u>

To identify age-varying transmissibility and susceptibility within the compartmental model,[21] we assumed a time-varying curve for the average contact numbers of ith age group with j^{th} age group (c_t^{ij}), which is estimated with the contact matrix between age groups through surveys conducted in Shanghai.[31,32] The surveys provided two different strengths of contact (before and during the epidemic). The first survey conducted in 2017 to 2018 in Shanghai was considered as a background of the strength of contact.[16] The second survey, with the same design, was conducted

during the epidemic (from February 1 to 10, 2020). The details of the modeling of the contact function (c_t^{ij}) are further described in the Supplementary Appendix.

Susceptibility-contact-transmissibility transmission process

When modeling transmission dynamics of infectious diseases, a key factor to consider is the probability of infection for a susceptible individual given contact with an infectious individual. Here, we separate this concept into two components: transmissibility (T) and susceptibility (s). We define transmissibility (T) as the infectiousness of one case. Theoretically, it is the secondary attack rate in their fully susceptible contacts ($s = 1$). Similarly, we define susceptibility (s) as the probability of acquiring infection from an infectious case ($T = 1$). Therefore, $s = 0$ corresponds to a situation in which the susceptible individuals are immune to the disease (this setting was later used to conduct a simulation study to assess possible age-dependent vaccination strategies if a certain age group were to achieve 100% immunity by vaccinations). We assumed that case transmissibility would depend on age and the presence of symptoms. To better quantify transmissibility and susceptibility, we introduced the estimated susceptibility (s_i) for i^{th} age group from a previous study as a prior in our model.[21] In this setting, the occurrence of a transmission event depends on both transmissibility of the index case and the susceptibility of the contact. The number of secondary cases (ρ) from one infectious case at unit time can be calculated as:

$$\rho = s \cdot \text{contact number} \cdot T$$

146 Let $T_{i,s}$ be the transmissibility of symptomatic infections in i^{th} age group. To
147 capture the age-dependent pattern, B splines basis functions were used to model the
148 variability in age-varying transmissibility smoothly. Given $T_{i,s}$, we assumed that the
149 age-varying transmissibility of asymptomatic infectious individuals was equivalent to
150 $T_{i,a} := \gamma_i T_{i,s}$, where $\gamma_i \leq 1$, i.e., the transmissibility of asymptomatic cases is no
151 stronger than that of symptomatic cases across different age groups, based on currently
152 available evidence[13,14,34]. The estimated mean of s_i and the B spline functions
153 mentioned above are shown in Table S3 and Figure S2 (in the Supplementary Appendix).
154
155 Asymptomatic infections
156 Our compartmental model (Figure 1) considered the transmission from
157 asymptomatic infections, which were often untraceable in the clinical survey and,
158 therefore, their contribution to population-level transmission would be underestimated.
159 To account for this, we assumed only a proportion of asymptomatic infections were
160 detected (R_{ca}^i), while others (R_h^i) would be unconfirmed (and not diagnosed) if
161 self-recovery occurred prior to diagnosis. We were able to observe disease confirmation
162 date but not the date of infection for the period from cases becoming infectious to the
163 diagnosis of COVID-19 ($\mathcal{A}_1^i$) in those with confirmed asymptomatic infection. Based on
164 the virus shedding pattern of asymptomatic infections reported in previous
165 studies,[12,14,35,36] we assumed that this period should be less than 30 days, after which
166 virus shedding generally ceases, and infection is no longer detectable through
167 pathogen-specific testing. As such, a uniform prior with an upper bound of 30 days was

168 adopted for $\mathcal{A}_1^i$. For the period from being infectious to becoming non-infectious

169 (negative conversion of virus shedding) in the undetected asymptomatic infections ($\mathcal{A}_2$),

170 we used a more informative log normal prior with a mean of 17 days and standard error

171 of 1.07 based on estimated parameters from a previous study.[12,14,35,36] The difference

172 between $\mathcal{A}_1^i$ and $\mathcal{A}_2$ would reflect the intensity of the contact tracing for different

173 ages. More details are provided in the Supplementary Appendix.

174

175 Model fitting

176 Let N_i be the total population of ith age group in Zhejiang province. Based on

177 the setting above, we defined a dynamic system for the 8×7 compartments, which is

178 shown in the equation (S3) (in the Supplementary). The state transitions in the

179 compartmental model are given in Figure 1. Based on our compartmental model, we

180 can estimate the secondary cases transmitted by symptomatic and asymptomatic

181 indexes respectively, which are used to evaluate the burden of both symptomatic and

182 asymptomatic transmission from different age groups. More details are given in the

183 equation (S4) and (S5) (in the Supplementary).

184

185 We built our model with features mentioned in above sections through a

186 Bayesian procedure for the estimation and inference of model parameters (listed in

187 Table S5).[37–39] Specifically, the compartmental model was fitted to the daily new

188 symptomatic and asymptomatic cases in Zhejiang province for each age group. The

189 Bayesian procedure with a Markov Chain Monte Carlo (MCMC) sampling algorithm also

190 utilized information relating to the COVID-19 transmission from other sources of
191 datasets, e.g. survey studies on the contact matrix, and estimated age-dependent
192 susceptibility from previous studies, therefore, the posterior distributions of parameters
193 could be elegantly extracted by the sufficient prior and sample evidence. More details of
194 the Bayesian model structure, assessment, and estimation of parameters are given in
195 the Supplementary Appendix. All analyses were implemented in R version 3.5.1.
196 Packages of deSolve,[40] extraDistr,[41] and splines[42] were used for model fitting.
197 Unless stated otherwise, the medians of the posterior distributions were used as the
198 point estimators of parameters and simulated numbers.

Results

Transmissibility

The estimated transmissibility presented an age-dependent difference between symptomatic and asymptomatic infections (Figure 2). While the transmission of symptomatic cases monotonically increased with increasing age, the transmissibility of asymptomatic infection remained low until age 40, after which point it significantly increased with increasing age. The age-varying ratios of the two kinds of transmissibility indicated asymptomatic cases were, on average, 66.72% lower in transmission than symptomatic cases. However, the difference between the two types of infections was not as big in those aged 0-20 and 60+ years old, but became more obvious in the middle-aged group where the ratios were as low as 24.42% and 23.38% for those aged 30-40 and 40-50 years old, respectively.

The proportion of asymptomatic cases

In Figure 3, the proportion of asymptomatic cases ($\frac{R_h^i+R_{ca}^i}{R_h^i+R_{cs}^i+R_{ca}^i}$) estimated by our model was much larger than what was observed in the data. The average proportion of asymptomatic cases was 28.22% (95%CI: 22.97% - 34.56%) of the total counts of cases in our model estimation, but was 9.24% in the observed data ($\frac{R_{ca}^i}{R_{cs}^i+R_{ca}^i}$). In our estimation from the empirical data, the highest proportion of asymptomatic case was among 0-10 (60.18% (95%CI: 53.61% - 66.99%)) and 10-20 (57.64% (95%CI: 47.45% – 66.98%)) years

old groups. For asymptomatic cases, we further estimated the proportion of cases that failed to be detected ($\frac{R_h^i}{R_h^i+R_{ca}^i}$). In the posterior samples, the average proportion of unconfirmed cases in all asymptomatic infections was 74.10% (95%CI: 65.85% - 80.72%). The maximum proportion of unconfirmed cases was observed in 20-30 years old at 86.59% (95%CI: 73.64% - 92.19%).

Symptomatic and asymptomatic transmission

To explore the impact of symptomatic and asymptomatic transmission, we present several features of the estimated dynamic of the epidemic and the transmission burden caused by symptomatic and asymptomatic cases in Figure 4. The estimated number of daily new transmissions reached a peak around ten days prior to the peak of the daily reported new confirmed cases (Figure 4A). We estimated a substantial number of undetected asymptomatic cases (109 (95%CI: 73 - 164)) were infected before the first asymptomatic case was diagnosed (January 27th) (Figure 4B). New transmissions were nearly eliminated by February 1st, 2020 (Figure 4A), when a comprehensive set of restrictions[19] had been implemented. The peak of the two types of transmission both occurred between January 17th to 21st (Figure 4C). The average burden of asymptomatic transmission during the major outbreak period was estimated to be 12.86% (95%CI: 7.54% - 19.27%). The burden of asymptomatic transmission increased with time, ranging from 7.77% to 16.03% (Figure 4D). Simulation studies were conducted to investigate the dynamic changes in the transmission burden over time during a prolonged epidemic (Figure S5). When the duration of the decreasing process of the contact function

242 (represented by "m" in Figure S1) was prolonged by two weeks and each individual's
243 daily contact number was increased by one person during the outbreak period, we
244 found a slower decreasing trend in daily new cases infected by asymptomatic cases
245 compared with that contributed by symptomatic cases (Figure S5, scenario 1).
246 Additional scenarios were generated demonstrating the possibility of asymptomatic
247 transmission dominating the total transmission under different conditions, especially
248 when the duration between symptom onset and disease confirmation for symptomatic
249 infections was shortened and the asymptomatic infections were not controlled (Figure
250 S5, scenarios 2 and 3).
251
252 Age-depended transmission
253 Within each age group, we observed heterogeneous transmission contributions
254 during different time periods (Figure 5A). Early on in the epidemic, the transmission
255 burden was dominated by persons of 50-60 years old (32.75% from January 7th to
256 January 11th), but the proportion of transmission contribution from people over 60 years
257 old significantly increased over time, surpassing the 50-60 years old and reaching 30.42%
258 by January 31st, 2020. The proportion of transmission contribution among varying age
259 groups was distinct between symptomatic and asymptomatic cases (Figure 5B). The
260 majority of both symptomatic and asymptomatic transmissions were contributed by
261 persons over 30 years old (Table S9). Individuals below 30 years old only contributed
262 less than 5% of all symptomatic transmission and approximately 12% of all
263 asymptomatic transmission, respectively, despite representing almost 40% of the entire

population. Contributions to asymptomatic transmission among 20-30 and >60 year age groups (9.44%, and 31.73%, respectively) were substantially higher than their corresponding contributions to symptomatic transmission (3.77%, and 26.55%, respectively). To further understand possible age-dependent vaccination strategies, a simulation of seven scenarios was conducted to assess the percentage decline in different age groups if one age group were to achieve 100% immunity by vaccinations (Figure S6). The results suggested that vaccinations targeting age groups above 30 years are likely to be more effective at the population level, with the most percentage decline of cases from the entire population achieved by targeting the 50-60 years old group. Meanwhile, vaccinating those younger than 30 years old are more likely to benefit their own age groups.

275 **Discussion**

276 In our study, we found that asymptomatic cases were over 60% less infectious
277 compared to symptomatic cases. While great efforts like mass screening and strict
278 contact tracing were conducted, our results suggested that a large proportion of
279 asymptomatic infections were still not detected.[43] The burden of asymptomatic
280 transmission was inferior in the early outbreak but could become higher with the
281 continuous spread of COVID-19. Under strained resources, age-specific prevention and
282 control strategies aimed at the middle age population may return greater
283 population-level benefits.

284

285 Current evidence suggests that asymptomatic COVID-19 cases are generally less
286 infectious[13] than cases with symptoms. We found that this difference may partially be
287 explained by patient age. Age may directly impact COVID-19 transmission through virus
288 shedding patterns[14] as discussed in previous studies.[44] Symptoms are commonly mild in
289 children[45] but severe in the elderly.[46] While still debatable,[47] higher severity has been
290 associated with increased shedding of the virus.[48] In our study, symptomatic and
291 asymptomatic cases were most infectious in individuals 60 years old or older. In
292 contrary to the monotonic increasing association between age and transmission in
293 symptomatic cases, there was a plateau of a low degree of transmission in young
294 asymptomatic infections. We suspect older adults are not only the most vulnerable to
295 succumb to COVID-19 but also may be more likely to transmit once infected, regardless
296 of symptom status. Interventions attempting to suppress asymptomatic transmission,

297 such as mask-wearing, should primarily focus on older adults if interventions to the
298 whole community are not feasible.
299
300 Similar to previous studies, our results suggest a small proportion of
301 asymptomatic cases have been detected since the start of the COVID-19 pandemic in
302 our setting.[49–51] Symptom-based screening has limited capability in asymptomatic case
303 detection,[6] while mass pathogen or immunological-based testing at the population-level
304 consumes tremendous health resources, and thus is not feasible in most settings.
305 Considering these challenges, age-dependent screening strategies may be more
306 practical. We found that the highest number of undetected asymptomatic cases was
307 among young adults aged 20 to 30 years old (Table S7) and the corresponding
308 transmission contribution was significantly higher than that of symptomatic case (Figure
309 5B). Young people were less likely to adhere to social distancing guidelines,[52] often had
310 mild symptoms or were asymptomatic after infection,[53] and were not prioritized in
311 prevention and controlling strategies.[54] Meanwhile, younger asymptomatic patients
312 were also more likely to have normal CAT scan findings, which may further complicate
313 case detection.[11] Case detection of asymptomatic COVID-19 cases based on current
314 control strategies implemented in this study is alarming.
315
316 Based on the estimated transmission contributions from symptomatic and
317 asymptomatic infections, roughly 13% of infections were associated with asymptomatic
318 transmission and that percentage continuously increased with a prolonged period. The

319 overall burden of transmission was mainly contributed by symptomatic cases at the
320 beginning of the epidemic, but asymptomatic infections appeared to have increasing
321 percentages of subsequent cases later on. Additional simulations suggested that the
322 transmission burden could even be dominated by asymptomatic transmissions under
323 certain circumstances (Figure S5). Therefore, the spreading potential of asymptomatic
324 cases cannot be ignored, especially in the later stages of the epidemic and in regions
325 where social distancing has not been mandated. Meanwhile, potential differences in
326 transmission burden by age groups, as shown in Figure 5 and S6, supports prioritizing
327 age-dependent prevention and control strategies when facing strained resources. As the
328 larger contributor to the transmission of COVID-19, the older age population is not only
329 a highly vulnerable group but should also be the primary target for prevention
330 strategies. Vaccine Strategies prioritizing the population between 30-60 years old are
331 likely to have the most population-level benefits.
332
333 There are several limitations in this study. First, data collection likely missed
334 potential cases of the epidemic, despite intensified efforts devoted by the local
335 investigation team to trace contacts. Due to this, we introduced a compartment in our
336 model (R_h^i) to adjust for poor case ascertainment and missing cases. Second,
337 transmissibility and susceptibility were two factors related to symptomatic and
338 asymptomatic transmission estimation and can be difficult to capture simultaneously.
339 We used the susceptibility estimates from a previous study[21] as priors in our model to
340 account for this parameter identification problem. Third, the contact survey data we

341 used in our model were obtained in Shanghai, a city adjacent to Zhejiang province.
342 Although the two regions share a similar culture and modes of social activities, there
343 were potential uncertainties associated with the discrepancies in contact matrices. To
344 address this limitation, we introduced a correction parameter in our model, so these
345 uncertainties were partially adjusted for in the analyses.
346
347 In summary, our results suggest individual-level transmissibility of COVID-19
348 increases with patient age, therefore targeting older age groups with prevention and
349 intervention strategies is expected to be more efficient. While asymptomatic cases are
350 difficult to trace, the burden of asymptomatic transmission is still sizable and should not
351 be ignored. The results from our study can be used to inform policy decisions on
352 pandemic control and safe reopening.

353 Ethics Statement

354 The research protocol was approved by the institutional review board at the

355 Zhejiang Provincial Center for Disease Control and Prevention.

356 **References**

357 1 Guan W-J, Ni Z-Y, Hu Y, *et al.* Clinical Characteristics of Coronavirus Disease
358 2019 in China. *N Engl J Med* 2020; **382**: 1708–20.

359 2 World Health Organization. WHO Coronavirus Disease (COVID-19)
360 Dashboard (12/12/2020). https://covid19.who.int (accessed Dec 12, 2020).

361 3 Ferguson N, Laydon D, Nedjati Gilani G, *et al.* Report 9: Impact of
362 non-pharmaceutical interventions (NPIs) to reduce COVID19 mortality and healthcare
363 demand. Imperial College London, 2020 DOI:10.25561/77482.

364 4 Prem K, Liu Y, Russell TW, *et al.* The effect of control strategies to reduce
365 social mixing on outcomes of the COVID-19 epidemic in Wuhan, China: a modelling
366 study. *The Lancet Public Health* 2020; **5**: e261–70.

367 5 Lewnard JA, Lo NC. Scientific and ethical basis for social-distancing
368 interventions against COVID-19. *The Lancet Infectious Diseases* 2020; **20**: 631–3.

369 6 Gandhi M, Yokoe DS, Havlir DV. Asymptomatic Transmission, the Achilles'
370 Heel of Current Strategies to Control Covid-19. *N Engl J Med* 2020; **382**: 2158–60.

371 7 Rothe C, Schunk M, Sothmann P, *et al.* Transmission of 2019-nCoV Infection
372 from an Asymptomatic Contact in Germany. *N Engl J Med* 2020; **382**: 970–1.

373 8 Holshue ML, DeBolt C, Lindquist S, *et al.* First Case of 2019 Novel
374 Coronavirus in the United States. *N Engl J Med* 2020; **382**: 929–36.

375 9 Hoehl S, Rabenau H, Berger A, *et al.* Evidence of SARS-CoV-2 Infection in
376 Returning Travelers from Wuhan, China. *N Engl J Med* 2020; **382**: 1278–80.

377 10 Wölfel R, Corman VM, Guggemos W, *et al.* Virological assessment of
378 hospitalized patients with COVID-2019. *Nature* 2020; **581**: 465–9.
379 11 Kronbichler A, Kresse D, Yoon S, Lee KH, Effenberger M, Shin JI.
380 Asymptomatic patients as a source of COVID-19 infections: A systematic review and
381 meta-analysis. *International Journal of Infectious Diseases* 2020; **98**: 180–6.
382 12 Han MS, Seong M-W, Kim N, *et al.* Viral RNA Load in Mildly Symptomatic
383 and Asymptomatic Children with COVID-19, Seoul, South Korea. *Emerging Infectious*
384 *Diseases* 2020; **26**: 2497–9.
385 13 Gao M, Yang L, Chen X, *et al.* A study on infectivity of asymptomatic
386 SARS-CoV-2 carriers. *Respir Med* 2020; **169**: 106026.
387 14 Kim SE, Jeong HS, Yu Y, *et al.* Viral kinetics of SARS-CoV-2 in asymptomatic
388 carriers and presymptomatic patients. *Int J Infect Dis* 2020; **95**: 441–3.
389 15 Moghadas SM, Fitzpatrick MC, Sah P, *et al.* The implications of silent
390 transmission for the control of COVID-19 outbreaks. *PNAS* 2020; **117**: 17513–5.
391 16 Li R, Pei S, Chen B, *et al.* Substantial undocumented infection facilitates the
392 rapid dissemination of novel coronavirus (SARS-CoV-2). *Science* 2020; **368**: 489–93.
393 17 Ferretti L, Wymant C, Kendall M, *et al.* Quantifying SARS-CoV-2
394 transmission suggests epidemic control with digital contact tracing. *Science* 2020; **368**.
395 DOI:10.1126/science.abb6936.
396 18 Hu Z, Song C, Xu C, *et al.* Clinical characteristics of 24 asymptomatic
397 infections with COVID-19 screened among close contacts in Nanjing, China. *Sci China Life*
398 *Sci* 2020; **63**: 706–11.

399 19 Huang L, Zhang X, Zhang X, *et al.* Rapid asymptomatic transmission of
400 COVID-19 during the incubation period demonstrating strong infectivity in a cluster of
401 youngsters aged 16-23 years outside Wuhan and characteristics of young patients with
402 COVID-19: A prospective contact-tracing study. *J Infect* 2020; **80**: e1–13.
403 20 Meng H, Xiong R, He R, *et al.* CT imaging and clinical course of
404 asymptomatic cases with COVID-19 pneumonia at admission in Wuhan, China. *J Infect*
405 2020; **81**: e33–9.
406 21 Davies NG, Klepac P, Liu Y, *et al.* Age-dependent effects in the transmission
407 and control of COVID-19 epidemics. *Nat Med* 2020; **26**: 1205–11.
408 22 Zhou R, Li F, Chen F, *et al.* Viral dynamics in asymptomatic patients with
409 COVID-19. *International Journal of Infectious Diseases* 2020; **96**: 288–90.
410 23 Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. *N Engl J Med* 2020;
411 published online May 15. DOI:10.1056/NEJMcp2009575.
412 24 Verity R, Okell LC, Dorigatti I, *et al.* Estimates of the severity of coronavirus
413 disease 2019: a model-based analysis. *Lancet Infect Dis* 2020; **20**: 669–77.
414 25 CDC COVID-19 Response Team. Severe Outcomes Among Patients with
415 Coronavirus Disease 2019 (COVID-19) - United States, February 12-March 16, 2020.
416 *MMWR Morb Mortal Wkly Rep* 2020; **69**: 343–6.
417 26 Kong D, Zheng Y, Wu H, *et al.* Pre-symptomatic transmission of novel
418 coronavirus in community settings. *Influenza Other Respir Viruses* 2020; **14**: 610–4.

419 27 Furukawa NW, Brooks JT, Sobel J. Evidence Supporting Transmission of
420 Severe Acute Respiratory Syndrome Coronavirus 2 While Presymptomatic or
421 Asymptomatic. *Emerg Infect Dis* 2020; **26**. DOI:10.3201/eid2607.201595.
422 28 Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic
423 proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond
424 Princess cruise ship, Yokohama, Japan, 2020. *Eurosurveillance* 2020; **25**.
425 DOI:10.2807/1560-7917.ES.2020.25.10.2000180.
426 29 Bai Y, Yao L, Wei T, *et al.* Presumed Asymptomatic Carrier Transmission of
427 COVID-19. *JAMA* 2020; **323**: 1406–7.
428 30 Bureau of Statistics. Zhejiang Provincial Bureau of Statistics: Sixth Census
429 Data. 2014; published online Sept 3.
430 http://tjj.zj.gov.cn/art/2014/9/3/art_1530851_20980968.html (accessed July 30, 2020).
431 31 Zhang J, Litvinova M, Liang Y, *et al.* Changes in contact patterns shape the
432 dynamics of the COVID-19 outbreak in China. *Science* 2020; **368**: 1481–6.
433 32 Zhang J, Klepac P, Read JM, *et al.* Patterns of human social contact and
434 contact with animals in Shanghai, China. *Scientific Reports* 2019; **9**: 15141.
435 33 Chong KC, Cheng W, Zhao S, *et al.* Monitoring disease transmissibility of
436 2019 novel coronavirus disease in Zhejiang, China. *International Journal of Infectious*
437 *Diseases* 2020; **96**: 128–30.
438 34 Luo L, Liu D, Liao X, *et al.* Contact Settings and Risk for Transmission in 3410
439 Close Contacts of Patients With COVID-19 in Guangzhou, China: A Prospective Cohort
440 Study. *Ann Intern Med* 2020; **173**: 879–87.

441 35 Long Q-X, Tang X-J, Shi Q-L, *et al.* Clinical and immunological assessment of
442 asymptomatic SARS-CoV-2 infections. *Nat Med* 2020; **26**: 1200–4.
443 36 Lee S, Kim T, Lee E, *et al.* Clinical Course and Molecular Viral Shedding
444 Among Asymptomatic and Symptomatic Patients With SARS-CoV-2 Infection in a
445 Community Treatment Center in the Republic of Korea. *JAMA Internal Medicine* 2020;
446 **180**: 1447–52.
447 37 Bolstad WM, Curran JM. Introduction to Bayesian statistics. John Wiley &
448 Sons, 2016.
449 38 Wikle CK, Berliner LM. A Bayesian tutorial for data assimilation. *Physica D:*
450 *Nonlinear Phenomena* 2007; **230**: 1–16.
451 39 Gelman A, Carlin JB, Stern HS, Dunson DB, Vehtari A, Rubin DB. Bayesian
452 Data Analysis, Third Edition. CRC Press, 2013.
453 40 Soetaert K, Petzoldt T, Setzer RW. Solving Differential Equations in R:
454 Package deSolve. *Journal of Statistical Software* 2010; **33**: 1–25.
455 41 Wolodzko T, Wolodzko MT. Package 'extraDistr'. 2017.
456 42 Perperoglou A, Sauerbrei W, Abrahamowicz M, Schmid M. A review of
457 spline function procedures in R. *BMC Medical Research Methodology* 2019; **19**: 46.
458 43 Flaxman S, Mishra S, Gandy A, *et al.* Estimating the effects of
459 non-pharmaceutical interventions on COVID-19 in Europe. *Nature* 2020; **584**: 257–61.
460 44 Esposito S, Principi N. To mask or not to mask children to overcome
461 COVID-19. *Eur J Pediatr* 2020; **179**: 1267–70.

462 45 Dong Y, Mo X, Hu Y, *et al.* Epidemiology of COVID-19 Among Children in
463 China. *Pediatrics* 2020; **145**: e20200702.
464 46 Zhou F, Yu T, Du R, *et al.* Clinical course and risk factors for mortality of
465 adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *The*
466 *Lancet* 2020; **395**: 1054–62.
467 47 He X, Lau EHY, Wu P, *et al.* Temporal dynamics in viral shedding and
468 transmissibility of COVID-19. *Nature Medicine* 2020; **26**: 672–5.
469 48 Liu Y, Yan L-M, Wan L, *et al.* Viral dynamics in mild and severe cases of
470 COVID-19. *The Lancet Infectious Diseases* 2020; **20**: 656–7.
471 49 Fauci AS, Lane HC, Redfield RR. Covid-19 — Navigating the Uncharted. *New*
472 *England Journal of Medicine* 2020; **382**: 1268–9.
473 50 García LF. Immune Response, Inflammation, and the Clinical Spectrum of
474 COVID-19. *Front Immunol* 2020; **11**: 1441.
475 51 Oran DP, Topol EJ. Prevalence of Asymptomatic SARS-CoV-2 Infection: A
476 Narrative Review. *Ann Intern Med* 2020; **173**: 362–7.
477 52 Czeisler MÉ, Tynan MA, Howard ME, *et al.* Public attitudes, behaviors, and
478 beliefs related to COVID-19, stay-at-home orders, nonessential business closures, and
479 public health guidance—United States, New York City, and Los Angeles, May 5–12, 2020.
480 *Morbidity and Mortality Weekly Report* 2020; **69**: 751.
481 53 Felsenstein S, Hedrich CM. COVID-19 in children and young people. *The*
482 *Lancet Rheumatology* 2020; **2**: e514–6.

483 54 Bedford J, Enria D, Giesecke J, *et al.* COVID-19: Towards controlling of a

484 pandemic. *The Lancet* 2020; **395**: 1015–8.

485

Tables and Figures

Table 1. The definitions of compartments.

Figure 1. Compartmental model for SARS-CoV-2 transmission, where "j" represents another age group different from "i" for the compartments.

Figure 2. (A) The estimated transmissibility and 95% credible intervals for each age group; (B) The ratios of asymptomatic transmissibility to symptomatic transmissibility for seven age groups.

Figure 3. The proportion of asymptomatic infections and unconfirmed asymptomatic infections until February 22nd, 2020 for seven age groups.

Figure 4. The estimated dynamics of the epidemic and the transmission burdens from symptomatic and asymptomatic cases. (A): The estimated numbers of daily new transmissions with 95% credible intervals and the observed numbers of daily reported new confirmed cases from January 7th to February 21st, 2020; (B) The observed numbers of daily reported new confirmed symptomatic (R_{cs}) and asymptomatic cases (R_{ca}) and the estimated numbers of daily new cases that failed to be detected (R_h) with 95% credible intervals; (C): The estimated numbers of infected individuals caused by symptomatic and asymptomatic transmission over time, with 95% credible intervals; (D): Corresponding proportions of symptomatic and asymptomatic transmissions over different time periods.

Figure 5. The burden of transmission caused by different ages. (A) The estimated (contribution) ratios of new transmissions from different ages over different time periods; (B) The estimated (contribution) ratios of symptomatic and asymptomatic transmission from different ages. The contribution ratio of each age group is calculated by the proportion of the transmissions caused by the corresponding age group to the number of all transmissions in each transmission type, from January 7th to February 1st, 2020.

Table 1. The definitions of compartments

Compartments	Meaning
S^i	Represents the individuals who are susceptible to the infectious disease.
E^i	Represents the individuals who are exposed to the infectious disease but are not infectious. The individuals of E would transfer to I_{ps} or I_a with proportion α_s^i and α_a^i for different ages after latent period $\mathcal{L}$.
I_{ps}^i	Represents the symptomatic infectious individuals before symptom onset, which would transfer to I_s^i after the period of pre-symptomatic transmission $\mathcal{S}_1$.
I_s^i	Represents the symptomatic infectious individuals after symptom onset, which would transfer to R_{cs}^i after the period of symptomatic transmission $\mathcal{S}_2^i$.
I_a^i	Represents the asymptomatic infectious individuals, which would transfer to R_{ca}^i (confirmed by testing after $\mathcal{A}_1^i$ days for different ages) or R_h^i (self-recovered after $\mathcal{A}_2$ days) eventually.
R_{cs}^i, R_{ca}^i and R_h^i	Represents the individuals assumed to be noninfectious and immune to the disease in the first wave of Zhejiang epidemic (roughly two months).

Figure 1. Compartmental model for SARS-CoV-2 transmission, where "j" represents another age group different from "i" for the compartments.



Figure 2. (A) The estimated transmissibility and 95% credible intervals for each age group; (B) The ratios of asymptomatic transmissibility to symptomatic transmissibility for seven age groups.



522 Figure 3. The proportion of asymptomatic infections and unconfirmed asymptomatic
523 infections until February 22nd, 2020 for seven age groups. The estimated proportions of
524 asymptomatic cases, the proportions of cases that failed to be detected among
525 asymptomatic infections (unconfirmed proportions), and the observed proportions of
526 asymptomatic cases are defined as: $\frac{R_h^i+R_{ca}^i}{R_h^i+R_{cs}^i+R_{ca}^i}$, $\frac{R_h^i}{R_h^i+R_{ca}^i}$, and $\frac{R_{ca}^i}{R_{cs}^i+R_{ca}^i}$, respectively. The
527 95% credible intervals for the estimated proportions of asymptomatic cases are shown
528 for each age group.



529

Figure 4. The estimated dynamics of the epidemic and the transmission burdens from symptomatic and asymptomatic cases. (A): The estimated numbers of daily new transmissions with 95% credible intervals and the observed numbers of daily reported new confirmed cases from January 7th to February 21st, 2020; (B) The observed numbers of daily reported new confirmed symptomatic (R_{cs}) and asymptomatic cases (R_{ca}) and the estimated numbers of daily new cases that failed to be detected (R_h) with 95% credible intervals; (C): The estimated numbers of infected individuals caused by symptomatic and asymptomatic transmission over time, with 95% credible intervals; (D): Corresponding proportions of symptomatic and asymptomatic transmissions over different time periods.



541 Figure 5. The burden of transmission caused by different ages. (A) The estimated
542 (contribution) ratios of new transmissions from different ages over different time
543 periods; (B) The estimated (contribution) ratios of symptomatic and asymptomatic
544 transmission from different ages. The contribution ratio of each age group is calculated
545 by the proportion of the transmissions caused by the corresponding age group to the
546 number of all transmissions in each transmission type, from January 7th to February 1st,
547 2020.



548